Skip to main content
NCBI home page
Heart logoLink to Heart
. 1997 Apr;77(4):319–324. doi: 10.1136/hrt.77.4.319

Poor clinical performance of the Wessex porcine heart valve bioprosthesis at nine years' follow up.

A Hurlé 1, J F Nistal 1, J M Revuelta 1
PMCID: PMC484724  PMID: 9155609

Abstract

OBJECTIVE: To assess the long term performance of the Wessex porcine bioprostheses implanted in a consecutive series of patients. DESIGN: A retrospective case series. PATIENTS: Between January 1985 and July 1991, 184 Wessex bioprostheses (78 mitral, 102 aortic, and 4 tricuspid) were implanted in 150 patients. The patients were 55% (83/150) male and 45% (67/150) female; mean age was 60 (SD 10) years. RESULTS: Hospital mortality was 9.3% (14/150). Total follow up was 696 patient-years (mean 4.7 years per patient). Linearised rates (events per 100 patient-years (SEM) for postoperative complications for patients with isolated mitral valve replacement, isolated aortic valve replacement, and multiple valve replacement were, respectively: late mortality: 4.7 (1.6), 3.3 (0.9), and 4.9 (1.9); thromboembolism: 5.8 (1.8), 3.0 (0.9), and 2.8 (1.4); valve thrombosis: 1.0 (0.7), 0.3 (0.3), and 0.7 (0.7); structural failure: 5.8 (1.7), 1.9 (0.7), and 7.1 (2.2). Actuarial freedom from complications at nine years (70% confidence interval) was: late mortality: 61 (9)%, 57 (13)%, and 59 (12)%; thromboembolism and valve thrombosis: 71 (9)%, 79 (6)%, and 81 (8)%; structural failure: 33 (14)%, 50 (16)%, and 12 (14)%; all valve related morbidity/mortality: 31 (10)%, 21 (11)%, and 7 (9)%. Stent fractures appeared in 11 of 17 explanted prostheses; actuarial freedom from stent fracture at nine years was 66 (12)%. CONCLUSIONS: The Wessex bioprosthesis is associated with high thrombogenicity, early structural dysfunction, and a high valve related morbidity/mortality which justifies very close follow up of patients fitted with them.

Full text

PDF
319

Images in this article

322Image
on p.322

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arom K. V., Nicoloff D. M., Kersten T. E., Northrup W. F., 3rd, Lindsay W. G., Emery R. W. Ten years' experience with the St. Jude Medical valve prosthesis. Ann Thorac Surg. 1989 Jun;47(6):831–837. doi: 10.1016/0003-4975(89)90014-3. [DOI] [PubMed] [Google Scholar]
  2. Arom K. V., Nicoloff D. M., Kersten T. E., Northrup W. F., 3rd, Lindsay W. G., Emery R. W. Ten-year follow-up study of patients who had double valve replacement with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg. 1989 Nov;98(5 Pt 2):1008–1016. [PubMed] [Google Scholar]
  3. Au J., Campanella C. Mitral prosthetic valve regurgitation due to stent fracture of a porcine bioprosthesis. Thorax. 1989 Mar;44(3):236–237. doi: 10.1136/thx.44.3.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bernal J. M., Rabasa J. M., Cagigas J. C., Echevarria J. R., Carrion M. F., Revuelta J. M. Valve-related complications with the Hancock I porcine bioprosthesis. A twelve- to fourteen-year follow-up study. J Thorac Cardiovasc Surg. 1991 May;101(5):871–880. [PubMed] [Google Scholar]
  5. Burdon T. A., Miller D. C., Oyer P. E., Mitchell R. S., Stinson E. B., Starnes V. A., Shumway N. E. Durability of porcine valves at fifteen years in a representative North American patient population. J Thorac Cardiovasc Surg. 1992 Feb;103(2):238–252. [PubMed] [Google Scholar]
  6. Edmunds L. H., Jr, Cohn L. H., Weisel R. D. Guidelines for reporting morbidity and mortality after cardiac valvular operations. J Thorac Cardiovasc Surg. 1988 Sep;96(3):351–353. [PubMed] [Google Scholar]
  7. Flemma R. J., Mullen D. C., Kleinman L. H., Werner P. H., Anderson A. J., Weirauch E. Survival and "event-free" analysis of 785 patients with Björk-Shiley spherical-disc valves at 10 to 16 years. Ann Thorac Surg. 1988 Mar;45(3):258–272. doi: 10.1016/s0003-4975(10)62460-5. [DOI] [PubMed] [Google Scholar]
  8. Gallo I., Nistal F., Blasquez R., Arbe E., Artiñano E. Incidence of primary tissue valve failure in porcine bioprosthetic heart valves. Ann Thorac Surg. 1988 Jan;45(1):66–70. doi: 10.1016/s0003-4975(10)62400-9. [DOI] [PubMed] [Google Scholar]
  9. Grunkemeier G. L., Starr A., Rahimtoola S. H. Prosthetic heart valve performance: long-term follow-up. Curr Probl Cardiol. 1992 Jun;17(6):329–406. [PubMed] [Google Scholar]
  10. Jones E. L., Weintraub W. S., Craver J. M., Guyton R. A., Cohen C. L., Corrigan V. E., Hatcher C. R., Jr Ten-year experience with the porcine bioprosthetic valve: interrelationship of valve survival and patient survival in 1,050 valve replacements. Ann Thorac Surg. 1990 Mar;49(3):370–384. doi: 10.1016/0003-4975(90)90240-7. [DOI] [PubMed] [Google Scholar]
  11. McKinnie J., Avitall B., Caceres J., Jazayeri M., Tchou P., Akhtar M. Electrophysiologic spectrum of concealed intranodal conduction during atrial rate acceleration in a model of 2:1 atrioventricular block. Circulation. 1989 Jul;80(1):43–50. doi: 10.1161/01.cir.80.1.43. [DOI] [PubMed] [Google Scholar]
  13. Pelletier L. C., Carrier M., Leclerc Y., Lepage G., deGuise P., Dyrda I. Porcine versus pericardial bioprostheses: a comparison of late results in 1,593 patients. Ann Thorac Surg. 1989 Mar;47(3):352–361. doi: 10.1016/0003-4975(89)90373-1. [DOI] [PubMed] [Google Scholar]
  14. Santalla A., Rodríguez-Bailón I., Calleja M., Tercedor L., Cervera S., Lara J., Moreno T. Valoración clínica y hemodinámica a medio plazo de las bioprótesis de Wessex y Hancock II. Rev Esp Cardiol. 1992 Jun-Jul;45(6):361–364. [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES